Effect of somatostatin receptor 2 antagonism on glucagon counterregulation during a hyperinsulinaemic euglycaemic-hypoglycaemic glucose clamp in adult men and women with long-standing type 1 diabetes: a randomised crossover phase 1 study

What Was Tested

This randomized controlled trial paper looks at Glucagon and Somatostatin.

The aim of this study was to determine the effect of a novel somatostatin receptor 2 (SSTR2) antagonist, ZT-01, on impaired glucagon counterregulation in hypoglycaemia and its safety in adults with type 1 diabetes.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and crossover study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

In the crossover set-up each of the participants took both Glucagon and the comparison in turn, acting as their own control.

Glucagon response was the primary endpoint; plasma glucose, other counterregulatory hormones, symptom scores and safety were also determined.

What Was Measured

The subject headings attached to it are Glucagon, Glucose Clamp Technique, Diabetes Mellitus, Type 1, Blood Glucose, Receptors, Somatostatin, Hypoglycemia and C-Peptide.

Author keywords: Counterregulation and Somatostatin receptor antagonist.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Glucagon and Somatostatin.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Diabetologia), a journal based in Germany.

More context: the Glucagon compound page and the Somatostatin compound page, all human trials.